Introduction
Mitochondria are complex organelles that perform a diverse array of important cellular functions, including: synthesis of ATP via oxidative phosphorylation (OXPHOS), calcium homeostasis and regulation of cell viability. Mitochondrial disease refers to a diverse constellation of conditions resulting from dysfunction of this essential organelle. These diseases are relatively common (∼1 in 10,000) and are devastating human conditions for which therapeutic options are limited and the prognoses remain extraordinarily poor. Mitochondrial encephalomyopathy is a common form of mitochondrial disease that results from mutations affecting genes encoding essential mitochondrial functions. Class I disorders are those directly affecting mitochondrial DNA (mtDNA) or nuclear genes encoding OXPHOS proteins (Leonard and Schapira, 2000a) . In contrast, class II disorders affect nuclear genes encoding mitochondrial proteins not directly functioning in OXPHOS or those encoding non-mitochondrial proteins associated with OXPHOS defects (Leonard and Schapira, 2000b) .
Recently, it has become evident that numerous neurological and neurodegenerative diseases, including Parkinson's disease (PD) and Huntington's disease (HD), are class II mitochondrial disorders (Burchell et al., 2010a; Burchell et al., 2010b) . Within the last year, research examining PINK and PARKIN pathogenesis has strongly supported the once controversial notion that PD is essentially a form of mitochondrial disease. Recent reviews have been written describing Drosophila research that has provided insight into PD pathogenesis (Park et al., 2009) . Since this excellent review it was discovered that PINK and PARKIN regulate protein turnover of Mfn (mitofusin; Poole et al., 2010; Ziviani et al., 2010) , explaining how these proteins alter mitochondrial morphology, which likely underlies mitochondrial dysfunction and disease pathogenesis. Additionally, numerous other mutants and transgenes have been generated, which affect mitochondrial localized proteins that model class II mitochondrial diseases 
